Can this covid-times saviour navigate the self-inflicted deep slump?
The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
Health on MSN11h
Doctors Explain When Flu-Like Symptoms Warrant an ER Visit
Most people will recover from viruses like the flu, COVID, and RSV without medical care, but some patients might need a trip ...
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
Novavax execs lay out 2025 game plan, talk ‘defining moment’ for business
Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.
‘We Were Told Nothing.’ What to Know About the Canceled Meeting to Discuss the Next Flu Shot
The meeting cancellation came one day before the CDC issued its weekly MMWR report, a scientific update on the latest ...
Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Hosted on MSN7h
Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial
Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...
Zacks Research Issues Positive Forecast for Pfizer Earnings
Equities researchers at Zacks Research raised their Q3 2025 earnings estimates for Pfizer in a report issued on Monday, February 24th. Zacks Research analyst K. Shah now forecasts that the ...